Skip to content
BMarker
TransactionsPerformanceSharingStocks & ETFsDemoPricingAPI Docs
Open app
Menu
TransactionsPerformanceSharingStocks & ETFsDemoPricingAPI Docs
Open app
  • CLS vs MRNA✓SelectedUSD · MRNACLS vs MRNA performance historyLatest closeAs of-0.77%11/16
Stock and ETF performance explorer

CLS vs MRNA

vs
1w1mo3mo6mo1y3y5y10yallcustom
Portfolio return
+750.2%
MRNA return
+179.0%
Excess return
+571.2%
Maximum drawdown
-56.5%

Performance

Returns, benchmark comparison, and relative performance.

Performance by timeframe

Returns for 3y.

Portfolio and benchmark returns by period
PeriodPortfolioMRNAExcessAlpha
1D-0.8%-3.6%+2.9%-0.6%
7D+7.0%-20.0%+27.0%+7.9%
30D-21.5%-1.3%-20.2%-21.5%
3M-28.8%+240.0%-268.8%-34.0%
6M-33.5%+339.0%-372.5%-41.9%
YTD-19.3%+630.0%-649.3%-37.1%
1Y-23.3%+769.1%-792.4%-42.1%
All+750.2%+179.0%+571.2%+587.7%

Cumulative growth

Daily Returns

Daily percentage return beside MRNA.

Daily Out/Under-Performance

Portfolio return minus MRNA return. Positive bars indicate outperformance.

Daily Alpha

Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.

Cumulative Out/Under-Performance

Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.

Cumulative Alpha

Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.

Updating return analytics…

3y analysis · Full analysis span regression · 6 months rolling